Use of synthetic vectors for neutralising antibody resistant delivery of replicating adenovirus DNA.

Use of synthetic vectors for neutralising antibody resistant delivery of replicating adenovirus DNA.

Use of synthetic vectors to deliver genomes of conditionally replicating lytic viruses combines the strengths of viral and non-viral approaches by enabling neutralising antibody resistant deployment of cancer virotherapy. Adenovirus is particularly suitable for this application since all proteins es...

Full description

Bibliographic Details
Main Authors:	Carlisle, R, Briggs, S, Hale, AB, Green, N, Fisher, K, Etrych, T, Ulbrich, K, Mautner, V, Seymour, L
Format:	Journal article
Language:	English
Published:	2006

Similar Items

Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
by: Fisher, K, et al.
Published: (2001)

Optimally stealthed Adenovirus serotype 5 shows enhanced activity and resistance to neutralisation
by: Thoma, C, et al.
Published: (2011)

Adenovirus hexon protein enhances nuclear delivery and increases transgene expression of polyethylenimine/plasmid DNA vectors.
by: Carlisle, R, et al.
Published: (2001)

Adenovirus hexon protein enhances nuclear delivery and increases transgene expression of polyethylenimine/plasmid DNA vectors
by: Carlisle, RC, et al.
Published: (2016)

Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer.
by: Green, N, et al.
Published: (2008)

Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy.
by: Fisher, K, et al.
Published: (2007)

Adenovirus type 5 interactions with human blood cells may compromise systemic delivery.
by: Lyons, M, et al.
Published: (2006)

Polymer-coated polyethylenimine/DNA complexes designed for triggered activation by intracellular reduction.
by: Carlisle, R, et al.
Published: (2004)

Polymer-coated polyplexes designed for triggered activation utilising intracellular reduction
by: Briggs, S, et al.
Published: (2004)

Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer.
by: Green, N, et al.
Published: (2012)

Ultrasound-enhanced delivery of polymer-coated oncolytic adenovirus for tumour growth inhibition
by: Carlisle, R, et al.
Published: (2011)

Cavitation-enhanced delivery of a replicating oncolytic adenovirus to tumors using focused ultrasound.
by: Bazan-Peregrino, M, et al.
Published: (2013)

Use of adenovirus proteins to enhance the transfection activity of synthetic gene delivery systems.
by: Carlisle, R
Published: (2002)

Coating of adeno-associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera.
by: Carlisle, R, et al.
Published: (2008)

Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor.
by: Morrison, J, et al.
Published: (2008)

Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins.
by: Bachtarzi, H, et al.
Published: (2011)

Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components.
by: Subr, V, et al.
Published: (2009)

Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1
by: Carlisle, R, et al.
Published: (2009)

Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1.
by: Carlisle, R, et al.
Published: (2009)

Retargeting adenovirus gene therapy via the epidermal growth factor receptor
by: Morrison, J, et al.
Published: (2006)

Systems for gene delivery based on combination of viral and non-viral vectors
by: Carlisle, R, et al.
Published: (2000)

Adenovirus type 5 (Ad5) is sequestered and inactivated by binding to coxsackievirus and adenovirus receptor (CAR) and complement receptor 1 (CR1) on human erythrocytes
by: Carlisle, R, et al.
Published: (2008)

Construction of recombinant adenovirus-5 vector to prevent replication-competent adenovirus occurrence
by: Wenbo Xie, et al.
Published: (2023-12-01)

Comparison of molecular strategies for breast cancer virotherapy using oncolytic adenovirus.
by: Bazan-Peregrino, M, et al.
Published: (2008)

Mechanisms of Rhinovirus Neutralisation by Antibodies
by: Lila Touabi, et al.
Published: (2021-02-01)

Mechanisms of rhinovirus neutralisation by antibodies
by: Touabi, Lila, et al.
Published: (2021)

Increased Adenovirus density for increased ultrasound-mediated delivery to tumors
by: Carlisle, R, et al.
Published: (2013)

Cavitation-enhanced delivery of a self-amplifying oncolytic adenovirus for tumour-selective cancer therapy.
by: Carlisle, R, et al.
Published: (2012)

The effect of polymer coating and different adenovirus serotypes on the innate immune responses to intraperitoneal adenovirus
by: Thoma, C, et al.
Published: (2008)

Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer.
by: Morrison, J, et al.
Published: (2009)

Neutralising antibodies against ricin toxin.
by: Julie Prigent, et al.
Published: (2011-01-01)

Adenovirus dodecahedron, as a drug delivery vector.
by: Monika Zochowska, et al.
Published: (2009-01-01)

Polymer coatings for delivery of nucleic acid therapeutics.
by: Laga, R, et al.
Published: (2012)

DNA delivery systems based on complexes of DNA with synthetic polycations and their copolymers
by: Oupický, D, et al.
Published: (2000)

Adenovirus: teaching an old dog new tricks.
by: Seymour, L, et al.
Published: (2011)

Aerosolized adenovirus-vectored vaccine as an alternative vaccine delivery method
by: Roy Chad J, et al.
Published: (2011-11-01)

Neutralising antibodies for Mayaro virus in Pantanal, Brazil
by: Alex Pauvolid-Corrêa, et al.
Published: (2015-02-01)

Schmallenberg virus neutralising antibody responses in sheep
by: Scott Jones, et al.
Published: (2019-11-01)

Induction of broadly neutralising HCV antibodies in mice by integration-deficient lentiviral vector-based pseudotyped particles.
by: Yao Deng, et al.
Published: (2013-01-01)

Polymer coatings for delivery of nucleic acid therapeutics
by: Laga, R, et al.
Published: (2012)